|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.0000 - 0.0000|
|52 Week Range|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
VANCOUVER , Dec. 5, 2019 /CNW/ - Pivot Pharmaceuticals Inc. today announced its corporate name change to BetterLife Pharma Inc. The Company will change its ticker symbol to BETR. BetterLife is committed to becoming a brand leader with its superior, proprietary phytocannabinoid and micronutrient product portfolio. " 2020 marks an important point in our evolution and this new branding reflects our commitment to commercialize science-based innovative medical formulations and to offer high quality preventive and self-care solutions to our customers," said Dr. Toni Rinow , CEO of BetterLife Pharma.
Pivot recognizes the importance of creating a market leading brand and Pivot is actively working with Joseph Mimran & Associates to brand and market the Pivot products in North America. "Pivot's future lies in the successful launch of its differentiated CBD product line using Pivot's patented technologies along with customer acceptance of its superior and proprietary phytocannabinoids products," said Dr. Rinow, CEO of Pivot. "With our team of scientists Pivot is focused on the development of value-added CBD and nutraceutical products.
VANCOUVER , Sept. 19, 2019 /CNW/ - Pivot Pharmaceuticals Inc. (CSE: PVOT /OTCQB: PVOTF / FRA: NPAT) ("Pivot" or the "Company"), is responding to the Stockwatch Article dated September 18, 2019 regarding the claims filed by Aly Ismail /Green Stream Botanicals Corp. ("Aly Ismail"). As of the date hereof, Pivot has not been served with the claim and Pivot strongly denies all allegations contained in the article and the claims by Aly Ismail as described in the article are without merit. Pivot further notes that neither Aly Ismail nor Green Stream Botanicals Corp. nor NH Transcendental Solutions Inc. are registrants under Canadian securities laws and thus any claim by Aly Ismail with respect to a finder's fee in connection with a private placement without the appropriate registration or exemption would constitute a breach by Aly Ismail of Canadian securities laws.
Individual and institutional investors as well as advisors are invited to log-on to VirtualInvestorConferences.com to view the presentations NEW YORK , Sept. 16, 2019 /PRNewswire/ -- Virtual Investor Conferences ...
VANCOUVER , Aug. 19, 2019 /CNW/ - Pivot Pharmaceuticals Inc. (CSE: PVOT / OTCQB: PVOTF / FRA: NPAT) is pleased to announce today that its board of directors has appointed Toni Rinow as Chief Executive Officer and Dr. Renz as Regional Manager Europe in addition to serving as its Chief Medical Officer. Under Dr. Toni Rinow's leadership, Pivot will be put on a path of accelerated revenue growth and global expansion in key cannabis markets in Canada , United States , and the European Union.
VANCOUVER , July 9, 2019 /PRNewswire/ - Pivot Pharmaceuticals Inc . (CSE: PVOT / OTCQB: PVOTF / FRA: NPAT ) ("Pivot" or the "Company") announces that it has hired Mr. Russell Starr ...
Pivot will use the remaining proceeds from the non-brokered private placement to execute on product manufacturing, distribution and sales beginning in the European Union, where regulations permit. Further, Pivot will use the proceeds to commence operations in Montreal, Canada where it is working with Health Canada to obtain its Standard Processor and Medical Sales Licenses. Concurrently with the closing of the Offering, Joe Mimran and Dr. Kenneth Kessler joined the Advisory Board of Pivot and Krisztian Toth joined the Board of Directors of Pivot as Executive Chairman and Dr. Joseph Borovsky will serve as the Lead Director.
Pivot's micellized CBD oral solution, is a revolutionary product for the emerging cannabis industry. SolMic's CEO, Dr. Wolfgang Schoenfeld stated, "The entire SolMic team is thrilled to be working with Pivot Pharma. Production of the miCelleBD oral solution has been initiated and our sales and marketing team has begun to take orders from clients, including from a network of 2,000 pharmacies in Germany and Switzerland .
Each Unit consists of one common share of the Company ("Common Share") and one Common Share purchase warrant of the Company ("Warrant"). Each whole Warrant shall be exercisable for a period of two years from the closing date of the Offering to purchase one Common Share at a price of $0.35 per Common Share.
The private placement will be of units at a price of $0.25 per unit, with each unit consisting of one common share and one common share purchase warrant ("Warrants") having a term of two years and an exercise price of $0.35. The private placement is expected to close in two tranches, with the first closing of $5 million within two weeks and the second tranche of $10 million closing within four weeks. Upon completion of the non-brokered private placement Pivot will issue 60,000,000 units to HPK. Completion of the private placement is conditional on HPK satisfactorily completing its due diligence investigation and High Park Ventures and Pivot entering into an advisory agreement pursuant to which High Park Ventures will provide Pivot with strategic advice.